Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 23,62 € (+120,13 %). La mediana es de 23,62 € (+120,13 %).
| Comprar |
10 |
| Mantener |
5 |
| Vender |
1 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Novocure presents turnaround plan with profitability targets and product launches
At the Morgan Stanley Healthcare Conference, Novocure unveiled a three-stage plan to achieve profitability and for the first time provided financial guidance, targeting adjusted EBITDA break-even by the end of 2025. The company reported 8% volume growth in its glioblastoma business, sees further upside in the US, and identifies Japan as its fourth-largest market. New product launches for pancreatic cancer (Optune Pax, CE mark in Europe) and non-small cell lung cancer are expected to drive growth; Novocure stresses it has roughly $440 million of liquidity to execute the plan. » Más en de.investing.com
NovoCure: market launches of Optune Pax gain momentum and drive international growth
NovoCure reported at the Wells‑Fargo conference increasing commercial momentum, particularly for Optune Pax in pancreatic cancer with about 600 prescriptions in four months and roughly 285 active patients. The company generated positive cash flow in Q2 2026 for the first time in years and is targeting a clear path to profitability alongside double‑digit revenue growth. Growth drivers also include Optune Gio for glioblastoma and expansion in Japan; risks remain reimbursement, competition from adagrasib, and a recent cybersecurity incident with limited impact. NovoCure is keeping R&D spending around $200 million and plans to hold sales and marketing costs stable, while additional approvals and guideline inclusions should support uptake. » Más en de.investing.com
NovoCure shows revenue growth but remains cash-flow negative as it expands TTFields devices
NovoCure’s Tumor Treating Fields devices, including Optune Gio and newly FDA-approved Optune Pax, drove revenue growth to about $655–704 million range, but the company posted a net loss (≈$136.2 million in FY2025) and negative free cash flow (−$75.7 million) as it invests in expansion. Debt and a near 0.9x debt-to-equity ratio, reliance on single-source suppliers, and expected negative free cash flow through 2027 pressure financing needs. Valuation looks more attractive than peer Omeros, but NovoCure faces execution and reimbursement risks that could limit near-term shareholder returns. » Más en finance.yahoo.com
Novocure shares fall after TRIDENT phase‑3 study – primary endpoint missed
The TRIDENT phase‑3 trial by Novocure did not meet its primary endpoint in newly diagnosed glioblastoma: median overall survival 17.7 vs. 17.5 months (hazard ratio 0.953; p=0.519) in 981 patients. The result prevents a potential expansion of Optune Gio use into the earlier radiochemotherapy phase, which had been seen as an important growth driver. Consequently, the stock plunged in pre‑market trading, exacerbated by a risk‑averse market environment after signals from the Fed. » Más en de.investing.com
NovoCure CEO sells 34,273 shares for about $615,000
Frank Leonard, CEO of NovoCure, reported an open-market sale of 34,273 common shares on June 4, 2026, for roughly $615,000. The sale reduced his direct holdings from 493,793 to 459,520 shares, representing 6.94% of his prior direct stake, and is his largest individual open-market sale to date. No indirect or derivative interests were affected; post-transaction direct holdings were valued at about $8.3 million. » Más en finance.yahoo.com
Datos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 170,74 M | 19,84 % |
| Beneficio bruto | 131,43 M | 25,93 % |
| Beneficio neto | -9,21 M | 70,99 % |
| EBITDA | 1,84 M | 108,18 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 1256,33 M € |
Número de acciones | 116,92 M |
Máximo/mínimo de 52 semanas | 19,48 € - 8,92 € |
| Dividendos | No |
Beta | 1,08 |
Ratio P/E | -11,16 |
Ratio PEG | -0,42 |
Ratio P/B | 3,94 |
Ratio P/S | 1,91 |
Perfil de la empresa
NovoCure Limited, una empresa de oncología, se dedica al desarrollo, la fabricación y la comercialización de dispositivos de campos de tratamiento tumoral (TTFields) para el tratamiento de cánceres de tumores sólidos en Estados Unidos, Europa, Oriente Medio, África, Japón y la Gran China. Sus dispositivos TTFields incluyen Optune para el tratamiento del glioblastoma, y Optune Lua para el tratamiento del mesotelioma pleural maligno. La compañía también tiene ensayos clínicos en curso o completados que investigan los TTFields en metástasis cerebrales, cáncer de estómago, glioblastoma, cáncer de hígado, cáncer de pulmón de células no pequeñas, cáncer de páncreas y cáncer de ovario. NovoCure Limited se constituyó en 2000 y tiene su sede en Saint Helier, Jersey.
| Nombre | NovoCure |
| CEO | Frank Leonard |
| Sede | Baar,
Israel |
| Sitio web | |
| Sector | Salud |
| Industria | Tecnología sanitaria |
| Salida a bolsa | 01/10/2015 |
| Empleados | 1605 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | NVCR |
Frankfurt | 038.F |
Düsseldorf | 038.DU |
München | 038.MU |